IMU - Imugene Limited

[Miner]

Looks like IMU will come out with some strong positives - speculating on its QBR published on 31 Oct.

 

[debtfree]

2024 CY Comp - Nov update.

IMU has been very disappointing and is the worst pick out of my 4 selections. Down 65% so far this year, nearly 12% down this month. It's knocked my average around a lot.

I can't see Dec making much difference to the return now. As I said before, very disappointing.

 

[access]

I'm still a believer.

 

[kenny]

Another recurring disappointment for my portfolio that tests my patience on the thesis that good biotech research takes time and money to reap outsized returns. IMU has secured another $46M in convertible notes and expects another $11M in FY 2023 R&D rebates. Will this be enough to bring one of their clinical trial candidates to commercialisation or outcomes good enough to attract M&A attention? That's the gamble for me.

 

[Dona Ferentes]

... secured another $46M in convertible notes and expects another $11M in FY 2023 R&D rebates. Will this be enough to bring one of their clinical trial candidates to commercialisation or outcomes good enough to attract M&A attention? That's the gamble for me.

Phase 1b ... a few hoops to jump through, still

03 Jan .. first Australian patient has been dosed in the Phase 1b clinical trial of its allogeneic CAR T-cell therapy azer-cel (azercabtagene zapreleucel), at the RPH in Sydney. The trial is focused on patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), one of the most challenging and aggressive forms of non-Hodgkin’s lymphoma.

Azer-cel is one of the few allogeneic CAR T-cell therapies currently being evaluated in Australia. Azer-cel offers an off-the-shelf alternative to traditional autologous CAR T-cell therapies, which require lengthy manufacturing processes involving a patient’s own cells. By utilising pre-manufactured donor T-cells, azer-cel has the potential to significantly shorten treatment timelines and expand accessibility for patients with limited options.

Imugene recently reported promising data from its US trial sites (ASX ann 02 Sept 2024), demonstrating the potential of azer-cel to deliver meaningful clinical outcomes. In the US cohorts, three patients achieved complete responses despite having relapsed following multiple prior treatments, including autologous CAR T therapies. Notably, patients treated in Cohort B – which includes lymphodepletion chemotherapy and interleukin-2 (IL-2) – have shown particularly robust and durable
responses, with responses extending beyond 90 and 120 days.